{"id":"W4389488043","doi":"10.1016/j.iotech.2023.100537","title":"65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Docetaxel; Medicine; Lenvatinib; Oncology; Chemotherapy; Internal medicine; Lung cancer; Phases of clinical research; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001293617,0.00154851,0.001992804,0.0005233922,0.0003968628,0.001709289,0.001331971,0.001502909,0.005763126],"category_scores_gemma":[0.0006890962,0.0007576459,0.001857969,0.0004309735,0.0009587822,0.0009368266,0.0004577366,0.004600973,0.001693649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001729448,"about_ca_system_score_gemma":0.001989347,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003057545,"about_ca_topic_score_gemma":0.007348665,"domain_scores_codex":[0.9996768,0.0001333924,0.00001286283,0.00005271674,0.00003096464,0.00009321779],"domain_scores_gemma":[0.9995834,0.00005978423,0.0000521905,0.00002675058,0.00002623318,0.0002516031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7706683,0.05692082,0.003842488,0.001329846,0.002876594,0.0002802814,0.0003385103,0.005300014,0.0317344,0.001039267,0.008220895,0.1174486],"study_design_scores_gemma":[0.704394,0.2760502,0.00712676,0.00006893422,0.0007473608,0.0002210988,0.00009743317,0.002485244,0.002680653,0.0004327917,0.00565104,0.00004461875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843313,0.00336001,0.0006551402,0.001000164,0.0004077831,0.002563345,0.002414806,0.0002055688,0.005061817],"genre_scores_gemma":[0.9733227,0.003466443,0.002179517,0.00170517,0.000211809,0.003542525,0.004483556,0.00006832887,0.01101995],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005763126,"threshold_uncertainty_score":0.01927954,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04270142033337985,"score_gpt":0.3679328438520774,"score_spread":0.3252314235186975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}